Network Meta-Analysis of Complement Inhibitors for Geographic Atrophy in Age-Related Macular Degeneration
In brief
Neither geographic atrophy drug slowed lesion growth more than the other
Across 13 trials involving 5,126 patients, pegcetacoplan and avacincaptad pegol showed no difference in slowing retinal lesion growth, although both reduced growth compared with sham in some analyses. Neither improved low-light vision, and some treatment regimens increased the risk of abnormal blood vessel growth. Because these are indirect comparisons with differences across trials, head-to-head studies are still needed.
- Journal
- Survey of ophthalmology (Q1)
- Published
- 19 November 2026
- Study design
- Systematic review / meta-analysis of RCTs
- Evidence level
- Level 1, High (CEBM 1a)
- Authors
- Fahad R Butt, Thanansayan Dhivagaran, Brendan K Tao, Abu B Butt, Fatima Abid, Anubhav Garg, et al.
- PMID
- 43057623
- DOI
- 10.1016/j.survophthal.2026.11.012
Why clinicians should know about it
- Picked for Ophthalmology (paper of the day, 22 November 2026): Network meta-analysis compares approved geographic atrophy therapies
Abstract
Pegcetacoplan (PEG) and avacincaptad pegol (ACP) are approved complement inhibitors for geographic atrophy (GA) secondary to age-related macular degeneration, yet direct comparative evidence is lacking. We conducted a PROSPERO-registered frequentist network meta-analysis of randomized controlled trials of complement inhibitors for GA. MEDLINE, Embase, and the Cochrane Library were searched through November 5, 2025. Twenty-two reports of 13 trials (5,126 patients) were included. Compared with sham, moderate-certainty evidence showed that PEG 15 mg monthly and every other month reduced untransformed GA lesion growth. ACP estimates were imprecise when reconstructed from arm-level data, but both ACP doses reduced GA growth when the trials' model-based treatment differences were used, consistent with the pivotal trials. No ACP and PEG regimens differed in GA growth, and no complement inhibitor improved low-luminance visual acuity. At final follow-up, PEG regimens and ACP 4 mg increased neovascular age-related macular degeneration compared with sham, and its incidence was lower with ACP 2 mg than with PEG 15 mg monthly in indirect comparison (low certainty), with no other ACP and PEG difference. These comparisons are limited by differences in trial populations, endpoints, and follow-up. Head-to-head trials with functional endpoints are needed.
Abstract as published, via PubMed.
For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.